What Is Cytokinetics, Incorporated (CYTK) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Cytokinetics, Incorporated's intrinsic value is estimated at $41.62, suggesting the stock is overvalued at its current price of $82.62. With 7 out of 9 models flagging downside (-49.6% average return), the market may be pricing in unsustainable growth. The most optimistic model, Markov DDM, places fair value at $143.07 (+73.2%), while Regime Cross — the most conservative — estimates $0.01 (-100.0%). This +173.2% gap reflects genuine analytical uncertainty about Cytokinetics, Incorporated's intrinsic worth. Among models with highest confidence, FTNN lean bearish — adding weight to the bearish side of the thesis.
What Do the Models Say About CYTK?
9 of 13 models are currently active for CYTK. Of these, 2 models suggest upside while 7 models suggest overvaluation. The Bayesian DCF estimates CYTK's intrinsic value at $37.68, implying -54.4% downside from the current price. See which stocks rank higher →
How Does CYTK Rank in Pharmaceutical Preparations?
Among 431 Pharmaceutical Preparations stocks, CYTK ranks #119 by Quality of Company score. CirclFi's QOC score of 6.1/10 evaluates 32 fundamental signals. A score of 6.1 indicates above-average quality.
See all Most Undervalued Pharmaceutical Preparations Stocks →
Within the Pharmaceutical Preparations space, Cytokinetics, Incorporated competes in an environment where patent cliff exposure often separates market leaders from laggards. Understanding these industry-specific dynamics is essential context for interpreting our model outputs.
Is CYTK a Value Trap?
CirclFi's Value Trap algorithm assigns CYTK a score of 38/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
9 of 13 models are active for Cytokinetics, Incorporated. Moderate coverage provides meaningful perspective. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi Quality of Company (QOC) framework, which evaluates 32 signals including margin stability, revenue growth trajectory, leverage, and free cash flow generation, Cytokinetics, Incorporated is rated at 6.1/10. This solid-tier score maintains reasonable quality metrics with some areas for improvement.
The gap between the most bullish and bearish model spans +173.2% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every CYTK valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across CYTK's 9 active models, average confidence is 40%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad